Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: A phase II study

Shirley Lewis, Supriya Chopra Sastri, Supreeta Arya, Shaesta Mehta, Prachi Patil, Shyamkishore Shrivastava, Reena Phurailatpam, Shailesh V. Shrikhande, Reena Engineer

Research output: Contribution to journalArticle

Abstract

Background: We report the response and outcomes of borderline resectable and locally advanced pancreatic cancer (BRPC & LAPC) patients treated with dose escalated neoadjuvant intensity modulated radiotherapy (IMRT). Methods: Thirty newly diagnosed patients with BRPC (n=18) and LAPC (n=12) (NCCN criteria V 2.2.12) were accrued in this prospective study from 2008-2011. All patients received neoadjuvant chemoradiation (NACRT) using Helical Tomotherapy (dose of 57 Gy over 25 fractions to the gross tumor volume (GTV) and 45 Gy over 25 fractions to suspected microscopic extension) along with weekly gemcitabine. Results: Fifteen patients (50%) had a partial response. A complete metabolic response (CMR) on PET was seen in 9 patients (30%). Among BRPC, 9 patients (50%) were surgically explored and 7 underwent R0 resection (39%). The median follow up of surviving patients was 85 [interquartile range (IQR): 64.5-85.8] months. The median progression free survival (PFS) was 13 months for BRPC and 8.8 months for LAPC. The median overall survival (OS) was 17.3 months for BRPC and 11.8 months for LAPC. Among patients undergoing R0 resection, the median PFS and OS was 27 and 35.5 months respectively. Conclusions: Dose escalated radiotherapy with concurrent chemotherapy is feasible and can downsize some tumors resulting in surgery in about 39% of the BRPC.

Original languageEnglish
Pages (from-to)474-482
Number of pages9
JournalJournal of Gastrointestinal Oncology
Volume10
Issue number3
DOIs
Publication statusPublished - 01-01-2019
Externally publishedYes

Fingerprint

Intensity-Modulated Radiotherapy
Pancreatic Neoplasms
Radiation
gemcitabine
Disease-Free Survival
Survival
Tumor Burden
Radiotherapy
Prospective Studies
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

Cite this

Lewis, Shirley ; Sastri, Supriya Chopra ; Arya, Supreeta ; Mehta, Shaesta ; Patil, Prachi ; Shrivastava, Shyamkishore ; Phurailatpam, Reena ; Shrikhande, Shailesh V. ; Engineer, Reena. / Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy : A phase II study. In: Journal of Gastrointestinal Oncology. 2019 ; Vol. 10, No. 3. pp. 474-482.
@article{1fb494b6d6494ae3894ff71db7c5ad99,
title = "Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: A phase II study",
abstract = "Background: We report the response and outcomes of borderline resectable and locally advanced pancreatic cancer (BRPC & LAPC) patients treated with dose escalated neoadjuvant intensity modulated radiotherapy (IMRT). Methods: Thirty newly diagnosed patients with BRPC (n=18) and LAPC (n=12) (NCCN criteria V 2.2.12) were accrued in this prospective study from 2008-2011. All patients received neoadjuvant chemoradiation (NACRT) using Helical Tomotherapy (dose of 57 Gy over 25 fractions to the gross tumor volume (GTV) and 45 Gy over 25 fractions to suspected microscopic extension) along with weekly gemcitabine. Results: Fifteen patients (50{\%}) had a partial response. A complete metabolic response (CMR) on PET was seen in 9 patients (30{\%}). Among BRPC, 9 patients (50{\%}) were surgically explored and 7 underwent R0 resection (39{\%}). The median follow up of surviving patients was 85 [interquartile range (IQR): 64.5-85.8] months. The median progression free survival (PFS) was 13 months for BRPC and 8.8 months for LAPC. The median overall survival (OS) was 17.3 months for BRPC and 11.8 months for LAPC. Among patients undergoing R0 resection, the median PFS and OS was 27 and 35.5 months respectively. Conclusions: Dose escalated radiotherapy with concurrent chemotherapy is feasible and can downsize some tumors resulting in surgery in about 39{\%} of the BRPC.",
author = "Shirley Lewis and Sastri, {Supriya Chopra} and Supreeta Arya and Shaesta Mehta and Prachi Patil and Shyamkishore Shrivastava and Reena Phurailatpam and Shrikhande, {Shailesh V.} and Reena Engineer",
year = "2019",
month = "1",
day = "1",
doi = "10.21037/jgo.2019.01.25",
language = "English",
volume = "10",
pages = "474--482",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "3",

}

Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy : A phase II study. / Lewis, Shirley; Sastri, Supriya Chopra; Arya, Supreeta; Mehta, Shaesta; Patil, Prachi; Shrivastava, Shyamkishore; Phurailatpam, Reena; Shrikhande, Shailesh V.; Engineer, Reena.

In: Journal of Gastrointestinal Oncology, Vol. 10, No. 3, 01.01.2019, p. 474-482.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy

T2 - A phase II study

AU - Lewis, Shirley

AU - Sastri, Supriya Chopra

AU - Arya, Supreeta

AU - Mehta, Shaesta

AU - Patil, Prachi

AU - Shrivastava, Shyamkishore

AU - Phurailatpam, Reena

AU - Shrikhande, Shailesh V.

AU - Engineer, Reena

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: We report the response and outcomes of borderline resectable and locally advanced pancreatic cancer (BRPC & LAPC) patients treated with dose escalated neoadjuvant intensity modulated radiotherapy (IMRT). Methods: Thirty newly diagnosed patients with BRPC (n=18) and LAPC (n=12) (NCCN criteria V 2.2.12) were accrued in this prospective study from 2008-2011. All patients received neoadjuvant chemoradiation (NACRT) using Helical Tomotherapy (dose of 57 Gy over 25 fractions to the gross tumor volume (GTV) and 45 Gy over 25 fractions to suspected microscopic extension) along with weekly gemcitabine. Results: Fifteen patients (50%) had a partial response. A complete metabolic response (CMR) on PET was seen in 9 patients (30%). Among BRPC, 9 patients (50%) were surgically explored and 7 underwent R0 resection (39%). The median follow up of surviving patients was 85 [interquartile range (IQR): 64.5-85.8] months. The median progression free survival (PFS) was 13 months for BRPC and 8.8 months for LAPC. The median overall survival (OS) was 17.3 months for BRPC and 11.8 months for LAPC. Among patients undergoing R0 resection, the median PFS and OS was 27 and 35.5 months respectively. Conclusions: Dose escalated radiotherapy with concurrent chemotherapy is feasible and can downsize some tumors resulting in surgery in about 39% of the BRPC.

AB - Background: We report the response and outcomes of borderline resectable and locally advanced pancreatic cancer (BRPC & LAPC) patients treated with dose escalated neoadjuvant intensity modulated radiotherapy (IMRT). Methods: Thirty newly diagnosed patients with BRPC (n=18) and LAPC (n=12) (NCCN criteria V 2.2.12) were accrued in this prospective study from 2008-2011. All patients received neoadjuvant chemoradiation (NACRT) using Helical Tomotherapy (dose of 57 Gy over 25 fractions to the gross tumor volume (GTV) and 45 Gy over 25 fractions to suspected microscopic extension) along with weekly gemcitabine. Results: Fifteen patients (50%) had a partial response. A complete metabolic response (CMR) on PET was seen in 9 patients (30%). Among BRPC, 9 patients (50%) were surgically explored and 7 underwent R0 resection (39%). The median follow up of surviving patients was 85 [interquartile range (IQR): 64.5-85.8] months. The median progression free survival (PFS) was 13 months for BRPC and 8.8 months for LAPC. The median overall survival (OS) was 17.3 months for BRPC and 11.8 months for LAPC. Among patients undergoing R0 resection, the median PFS and OS was 27 and 35.5 months respectively. Conclusions: Dose escalated radiotherapy with concurrent chemotherapy is feasible and can downsize some tumors resulting in surgery in about 39% of the BRPC.

UR - http://www.scopus.com/inward/record.url?scp=85066929118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066929118&partnerID=8YFLogxK

U2 - 10.21037/jgo.2019.01.25

DO - 10.21037/jgo.2019.01.25

M3 - Article

AN - SCOPUS:85066929118

VL - 10

SP - 474

EP - 482

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 3

ER -